BCL2L11 and chronic myelogenous leukemia, BCR-ABL1 positive: In a mouse CML model, the BIM/MCL-1 ChNPs and dasatinib combination therapy suppressed proliferation of BCR-ABL + hematopoietic cells and prevented leukemic infiltration of organs.